Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
中文摘要

《亚洲男性学杂志》 2013; 15 (4): 466-470

接受前列腺癌根治术和随后短期辅助雄激素剥夺治疗的临床局限性前列腺癌患者的睾酮恢复动力学

Bo Dai, Yuan-Yuan Qu, Yun-Yi Kong, Ding-Wei Ye, Xu-Dong Yao, Shi-Lin Zhang, Hai-Liang Zhang and Wei-Yi Yang (中国)

内分泌治疗为转移性、复发性及局部进展性前列腺癌的标准治疗方案。为了探讨局部进展性前列腺癌患者接受前列腺癌根治术联合短期辅助内分泌治疗后血清睾酮的恢复情况,我们前瞻性地收集95例在我院接受前列腺癌根治术联合9个月辅助内分泌治疗的局部进展性前列腺癌患者资料。在患者接受内分泌治疗前,内分泌治疗停止时以及内分泌治疗停止后1个月、3个月、6个月、9个月和12个月时分别检测患者血清睾酮水平。利用Cox比例风险模型分析患者临床病理特征与内分泌治疗停止后血清睾酮恢复的相关性。本组患者中位年龄67岁,辅助内分泌治疗前血清睾酮中位值为361(230~905)ng dl-1。全组患者前列腺癌根治术后均接受了9个月的辅助内分泌治疗而且血清睾酮均达到去势水平(<50 ng dl-1)。内分泌治疗停止3个月时,97.9%的患者血清睾酮恢复至去势以上水平(>50 ng dl-1),36.9%的患者血清睾酮恢复至正常水平(≥230 ng dl-1)。内分泌治疗停止6个月、9个月及12个月时,血清睾酮恢复至正常水平的患者所占比例分别为66.3%、86.3%及92.6%。Cox多因素回归分析结果显示,仅较高的基线睾酮水平(≥300 ng dl-1)与内分泌治疗停止后血清睾酮较快恢复至正常水平相关(HR=1.98;P=0.012)。综上所述,本研究结果显示多数患者在内分泌治疗停止3个月时血清睾酮恢复至去势以上水平(>50 ng dl-1),而在内分泌治疗停止9个月时多数患者血清睾酮能够恢复至正常水平。基线睾酮水平较高的患者内分泌治疗停止后血清睾酮能够较快地恢复至正常水平。

关键词:雄激素剥夺治疗(ADT),促黄体激素释放激素,前列腺肿瘤,恢复功能,睾酮

此摘要文献来源:
Bo Dai, Yuan-Yuan Qu, Yun-Yi Kong, Ding-Wei Ye, Xu-Dong Yao et al. Kinetics of testosterone recovery in clinically localized prostate cancer
patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy. Asian J Androl 2013; 15: 466-70.

 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.